Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: A prospective cohort study

Blood

Volumn 99, Issue 6, 2002, Pages 1938-1942

  Simioni, Paolo ^a,b   Tormene, Daniela ^a   Prandoni, Paolo ^a   Zerbinati, Patrizia ^a   Gavasso, Sabrina ^a   Cefalo, Philip ^a   Girolami, Antonio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Department of Medical and Surgical Sciences ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; GENE PRODUCT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADOLESCENT; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; FAMILY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ANALYSIS; GENETIC RISK; GENETIC SCREENING; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PEDIGREE; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0037085791     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.6.1938     Document Type: Article

References (29)

1. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study
2. Resistance to activated protein C as a basis for venous thrombosis
3. The risk of recurrent venous thromboembolism in patients with an Arg 506G mutation in the gene for factor V Leiden (factor V Leiden)
4. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)
5. Factor V Leiden mutation and the risks for thromboembolic disease: A clinical perspective
6. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men
7. Activated protein C resistance as an additional risk factor for thrombosis in protein C deficient families
8. Additional genetic risk factors for venous thromboembolism in carriers of the factor V Leiden mutation
9. Interrelation of hyper-homocystinemia, factor V Leiden, and risk of future venous thromboembolism
10. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia
11. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis
12. Incidence of venous thromboembolism in families with inherited thrombophilia
13. A prospective study of the incidence of deep-vein thrombosis within a defined urban population
14. Non-invasive diagnostic tests for the diagnosis of clinically suspected deep-vein thrombosis
15. The diagnosis of pulmonary embolism
16. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: A prospective cohort study
17. Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant
18. Hyperhomocystinemia and deep-vein thrombosis: A case-control study
19. Prevalence of antiphospholipid antibodies and lupus anticoagulant in juvenile patients with objectively documented deep vein thrombosis
20. Low rate of venous thromboembolism in asymptomatic relatives of probands with factor V Leiden
21. Deep vein thrombosis and pulmonary embolism in the general population
22. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism
23. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT)
24. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism
25. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium
26. The role of inherited thrombophilia in venous thromboembolism associated with pregnancy
27. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation
28. Factor V Leiden: Should we screen oral contraceptive users and pregnant women?
29. Homozygous patients with APC-resistance may remain paucisymptomatic or asymptomatic during oral contraception